Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2018-04-26 / Front Oncol 2018;8:127Immunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2018-04-20 / Oncol Res Treat 2018;41(5):292-297Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2018-04-11 / Sci Transl Med 2018 Apr;10(436)WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2018-04-01 / Anticancer Res. 2018 04;38(4):2217-2225Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-1910Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-26 / Oncoimmunology 2018;7(7):e1445457Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-03-26 / J Immunol Res 2018;2018:8740976Dendritic cells as cancer therapeutics
/in Dendritic Cells, International Publications /von 2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-88
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de